Patent reform passes House
This article was originally published in The Gray Sheet
Executive Summary
Patent reform act (H.R. 1908) passes House Sept. 7 by a vote of 220-175. Device stakeholders are concerned that the bill limits the factors judges may consider when awarding damages for infringement, giving too much weight to the value of the individual patent instead of the entire product. The Bush administration opposes the bill as long as the so-called "apportionment" language remains. The House passed five amendments, including one offered by John Conyers, D-Mich., which among other revisions seeks to clarify that apportionment is not mandatory and other criteria may be considered. Another amendment requires the Patent Office to study over the next year trends in how damages have been awarded in recent court cases. The Senate has yet to vote on its version of the legislation, S. 1145 (1"The Gray Sheet" July 23, 2007, p. 19)...
You may also be interested in...
Proposed Patent Reform Bill Would Codify Georgia-Pacific Factors
Sen. Jon Kyl, R-Ariz., plans to soon introduce a patent damages bill that does not include the apportionment provisions opposed by the medical device industry and contained in legislation sponsored by Sen. Patrick Leahy (S. 1145)
Patent Reform Bills Clear House And Senate Judiciary Committees
The House and Senate Judiciary Committees each approved versions of patent reform legislation last week that respond to some concerns raised by device and drug lobbyists, but industry will seek more changes before the bills go to a floor vote
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip